Completed PHASE4 INTERVENTIONAL NCT01201343

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Multiple Sclerosis, Relapsing, Remitting

Updated 6 times since 2017 Last updated: Dec 2, 2013 Started: Jan 31, 2005 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01201343, this PHASE4 trial focuses on Multiple Sclerosis, Relapsing, Remitting and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2019 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.